INCIVO

Opinions on drugs - Posted on Oct 14 2014

Reason for request

Re-assessment of the actual benefit and improvement in actual benefit at the request of the Transparency Committee in accordance with Article R 163-21 of the French Social Security Code

Clinical Benefit

Substantial

Clinical Added Value

minor

In the treatment of chronic hepatitis C due to genotype 1 HCV in adult patients with compensated liver disease, INCIVO in combination with dual therapy with peginterferon alfa and ribavirin provides a minor improvement in actual benefit (Level IV) in comparison with this dual therapy.